Oxford BioDynamics Plc has generated over 1.5 billion datapoints and approximately 1.1 million conserved 3D genomic conformations from more than 18,000 samples across over 40 disease areas.
Public source
Publisher name
Public post
The last post ended with two things the genomics field already has: millions of whole genomes, and the biological samples behind many of them. Start with the samples. Ox…
Company
Oxford BioDynamics Plc
Advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
- Industry
- Biotechnology Research
- Location
- Oxford, GB
- Company size
- 51–200 employees
About Oxford BioDynamics Plc
Oxford BioDynamics (OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. OBD aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare with a portfolio of clinical tests and research tools based on its proprietary EpiSwitch® technology, uniquely capable of reproducibly translating 3D genome regulation for clinical application. The company’s flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible. OBD’s 24,000 sq ft headquarters in Oxford, UK, houses offices and state-of-the-art laboratory facilities. OBD’s commercial team has an office in Gaithersburg, MD, USA, and the company has an ISO-certified laboratory in Penang, Malaysia. OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from 10,000+ samples in 30+ human diseases. OBD’s proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone may respond to a disease or treatment. For more information, please visit oxfordbiodynamics.com.
See moreLatest activity
Latest activity from Oxford BioDynamics Plc
6 signals
Research & Knowledge
Oxford BioDynamics Plc led a new peer-reviewed study in the Journal of Translational Medicine led by the University of East Anglia, showing five conditions linked to profound fatigue with little overlap at the individual gene level but converging on the same underlying regulatory circuitry when analysed with EpiSwitchOrion.
Research & Knowledge
Oxford BioDynamics Plc published a study using EpiSwitch Orion, an AI-enabled discovery platform, in the Journal of Translational Medicine.
Research & Knowledge
Oxford BioDynamics Plc published a study by researchers at the University of East Anglia, the London School of Hygiene and Tropical Medicine, and the Cornwall Partnership NHS Foundation Trust, funded by Oxford BioDynamics Plc, in the Journal of Translational Medicine.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
HudsonAlpha Institute for Biotechnology
HudsonAlpha Institute for Biotechnology Dr. Sara Cooper and her team are studying the complexities of breast and ovarian cancers with a focus on metastatic and chemoresistant cancer through genomics and personalized cancer research.
Research & Knowledge
Oxford Nanopore Technologies
Oxford Nanopore Technologies published a case study on researchers using Oxford Nanopore sequencing to uncover hidden cancer signals for earlier detection and monitoring.
Research & Knowledge
Genomics England
Genomics England published new research showing that making genomic datasets more ancestrally diverse could make rare conditions diagnoses fairer and more accurate for everyone.
Research & Knowledge
Crown Bioscience
Crown Bioscience conducted a multi-omic comparison of preclinical cancer models, integrating transcriptomic, proteomic, and genomic data from over 10,000 primary tumors and nearly 4,000 preclinical models.
Research & Knowledge
Altum Sequencing